Trulicity vs Ozempic: Which Once-Weekly GLP-1 for Type 2 Diabetes?

The same class, different engineering

Both drugs are GLP-1 receptor agonists for once-weekly subcutaneous injection. Both work through the same biology: appetite suppression, slowed gastric emptying, glucose-dependent insulin release, glucagon suppression at high blood sugar. Both are approved by the FDA only for type 2 diabetes — neither has an obesity indication (Wegovy and Zepbound fill that gap with the same molecules at higher doses).

The structural difference is how each molecule was engineered to last a week:

• Trulicity (dulaglutide) is a peptide-protein fusion — two GLP-1 analog peptides linked to an Fc fragment of human IgG4 antibody. The antibody fragment extends half-life to about 5 days via FcRn recycling. We cover this in detail in our dulaglutide plain-English explainer.
• Ozempic (semaglutide) is a peptide with a fatty-acid chain attached, which binds albumin in blood and produces ~7-day half-life through albumin's slow clearance.

Different chemistry, similar practical outcome (weekly dosing), but the receptor-activation potency at approved doses ends up meaningfully different.

Efficacy: HbA1c and weight loss

The SUSTAIN-7 head-to-head trial (2017) compared semaglutide directly with dulaglutide in patients with type 2 diabetes over 40 weeks. The result was clearly in semaglutide's favor:

• HbA1c reduction: semaglutide 1.0 mg produced approximately 1.8% reduction; dulaglutide 1.5 mg produced approximately 1.4%.
• Weight loss: semaglutide 1.0 mg produced approximately 6.5 kg; dulaglutide 1.5 mg produced approximately 3.0 kg.

Higher doses of each drug have come to market since (Ozempic now goes to 2.0 mg; Trulicity to 4.5 mg), but the broad pattern holds: at any comparable exposure level, semaglutide produces deeper glycemic and weight effects.

For patients optimizing for HbA1c reduction and weight loss, Ozempic is the stronger choice on this dimension.

Cardiovascular outcomes: where Trulicity has a real argument

This is the dimension where Trulicity's case is strongest. The REWIND cardiovascular outcomes trial (Gerstein et al., Lancet 2019) was unusual among GLP-1 cardiovascular trials in two important ways.

Population: REWIND enrolled patients with type 2 diabetes who had either established cardiovascular disease (31% of the cohort) or just multiple risk factors (69% of the cohort). Most cardiovascular outcomes trials enroll only the higher-risk established-disease group. REWIND demonstrated benefit in the broader, primary-prevention-leaning population.

Result: Dulaglutide reduced major adverse cardiovascular events by 12% (HR 0.88, p=0.026) over a median 5.4-year follow-up.

Semaglutide's cardiovascular evidence base in T2D is SUSTAIN-6 (2016), which showed 26% MACE reduction but in an exclusively established-cardiovascular-disease population. Both are real CV benefit signals; Trulicity's evidence reaches a broader patient profile, while Ozempic's effect size in the higher-risk population is larger.

For type 2 diabetes patients with risk factors but no established cardiovascular disease, Trulicity has the most directly-applicable evidence. For higher-risk populations, the choice is more even.

Side-effect profile and tolerability

Both drugs share the standard GLP-1 GI side-effect profile — nausea, vomiting, constipation, diarrhea, concentrated during titration. Differences:

Trulicity: nausea is generally milder at standard doses. Real-world tolerability is well-documented after a decade of use; patients who could not tolerate higher-potency drugs sometimes do well on Trulicity.

Ozempic: nausea is more intense at comparable receptor activation, partly because the deeper appetite suppression and slowed gastric emptying produces more pronounced GI effects. Higher rates of treatment-emergent nausea in trials.

Both share class-level warnings: rodent thyroid C-cell tumor signal, rare pancreatitis risk, gallbladder effects.

Dosing and practical considerations

Both come as single-dose pre-filled pens or autoinjectors. Trulicity's pen is widely regarded as the simplest in the class — a hidden needle and a one-button design that is approachable for needle-averse patients.

Insurance and switching

Insurance coverage usually treats Trulicity and Ozempic as different products requiring separate prior authorization, even though both are once-weekly GLP-1s. Switching between them is straightforward clinically: discontinue one, start the other at the next scheduled dose, allow 2-4 weeks for the new drug to reach steady state.

The more consequential switching question in 2026 is whether to move from either to Mounjaro/Zepbound (tirzepatide), which produces deeper effects than both. That decision is covered in our switching guide.

The honest read

For new prescribing for type 2 diabetes in 2026, Ozempic is generally the stronger choice on glycemic and weight-loss dimensions, with comparable cardiovascular benefit in higher-risk populations. Trulicity has a defensible position for patients with cardiovascular risk factors but not established disease (where REWIND's broader population evidence is decisive), patients with milder T2D where the conservative dosing curve fits, and patients already stable on Trulicity with no compelling reason to switch.

For weight loss as the primary goal, neither is the right choice — Wegovy (semaglutide at higher dose) or Zepbound (tirzepatide) have the dedicated obesity approval and the deeper outcomes data.